Consensus document on acute-on-chronic liver failure (ACLF) established by the Mexican Association of Hepatology
Ann Hepatol. 2023 Jul 21:101140. doi: 10.1016/j.aohep.2023.101140. Online ahead of print.ABSTRACTAcute-on chronic liver failure (ACLF) has been an intensively debated topic mainly due to the lack of a unified definition and diagnostic criteria. The growing number of publications describing the mechanisms of ACLF development, the progression of the disease, outcomes and treatment has contributed to a better understanding of the disease, however, it has also sparked the debate about this condition. As an attempt to provide medical professionals with a more uniform definition that could be applied to our population, the first...
Source: Annals of Hepatology - July 23, 2023 Category: Gastroenterology Authors: Aldo Torre Laura Esthela Cisneros Garza Mauricio Castillo Barradas Nalu Navarro-Alvarez R Sandoval Salas Mar ía Sarai González Huezo Jos é Luís Pérez Hernández Osvely M éndez-Guerrero Jes ús Alejandro Ruiz Manríquez Rafael Trejo Estrada Norberto Source Type: research
A novel nomogram for predicting microvascular invasion in hepatocellular carcinoma
CONCLUSIONS: We constructed and evaluated the performance of the novel nomogram for predicting MVI risk. Our predictive model could adequately predict MVI risk and aid clinicians in selecting appropriate therapeutic strategies for patients.PMID:37479060 | DOI:10.1016/j.aohep.2023.101136 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 21, 2023 Category: Gastroenterology Authors: Yuan Chang Tianyu Guo Bo Zhu Yefu Liu Source Type: research
Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: what's new 12 months later?
CONCLUSIONS: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.PMID:37468096 | DOI:10.1016/j.aohep.2023.101141 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Cl émence Hollande H élène Regnault Lorraine Blaise Nathalie Ganne-Carri é Val érie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne Fran çois Paye Pie Source Type: research
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research
Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: what's new 12 months later?
CONCLUSIONS: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.PMID:37468096 | DOI:10.1016/j.aohep.2023.101141 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Cl émence Hollande H élène Regnault Lorraine Blaise Nathalie Ganne-Carri é Val érie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne Fran çois Paye Pie Source Type: research
Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists
CONCLUSIONS: The observation of a lower LSM in people taking SGLT2i and/or GLP-1a following adjustment for other relevant clinico-demographic variables provides support for clinical trials to assess their efficacy in reducing the progression of NAFLD.PMID:37468097 | DOI:10.1016/j.aohep.2023.101142 (Source: Annals of Hepatology)
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Lucy Gracen Withma Muthukumara Melanie Aikebuse Anthony Russell James O'Beirne Katharine M Irvine Suzanne Williams Gaurav Puri Patricia C Valery Kelly L Hayward Elizabeth E Powell Source Type: research
Metabolic dysfunction: The silenced connection with fatty liver disease
Ann Hepatol. 2023 Jul 17:101138. doi: 10.1016/j.aohep.2023.101138. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) represents a global public health burden. Despite the increase in its prevalence, the disease has not received sufficient attention compared to the associated diseases such as diabetes mellitus and obesity. In 2020 it was proposed to rename NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in order to recognize the metabolic risk factors and the complex pathophysiological mechanisms associated with its development. Furthermore, along with the implementation of the pr...
Source: Annals of Hepatology - July 19, 2023 Category: Gastroenterology Authors: Mariana M Ram írez-Mejía Xingshun Qi Ludovico Abenavoli Manuel Romero-G ómez Mohammed Eslam Nahum M éndez-Sánchez Source Type: research
